Meeting
2023 ASCO Annual Meeting
A phase 1B dose escalation study of ETC-159 in combination with pembrolizumab in advanced or metastatic solid tumours.
Authors
David Shao Peng Tan
National University Cancer Institute, Singapore and Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore
David Shao Peng Tan , Matthew C.H. Ng , Vivek Subbiah , Wells A. Messersmith , John H Strickler , veronica diermayr , Julienne Cometa , Stephanie Blanchard , Ranjani Nellore , Vishal Pendharkar , Bong Hwa Gan , Nurul Nazihah Rozaini , Claudia Koh , Suman Sarma , Huay Mei Poh , Alexander Lezhava , VENKATESHAN SRIRANGAM PRATIVADIBHAYANKARAM
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Developmental Therapeutics—Immunotherapy
Track
Developmental Therapeutics—Immunotherapy
Sub Track
PD1/PD-L1 Inhibitor Combinations
Clinical Trial Registration Number
NCT02521844
Citation
J Clin Oncol 41, 2023 (suppl 16; abstr 2601)
DOI
10.1200/JCO.2023.41.16_suppl.2601
Abstract #
2601
Poster Bd #
443
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
A phase 1 dose-escalation study to investigate the safety, efficacy, pharmacokinetics, and pharmacodynamic activity of cln-619 (Anti-MICA/B antibody) alone and in combination with pembrolizumab in patients with advanced solid tumors.
First Author: Judy S. Wang
Poster
2022 ASCO Annual Meeting
A phase 1 dose-escalation study to investigate the safety, efficacy, pharmacokinetics, and pharmacodynamic activity of CLN-619 (anti-MICA/MICB antibody) alone and in combination with pembrolizumab in patients with advanced solid tumors.
First Author: John D. Powderly
Poster
2021 ASCO Annual Meeting
A phase 1 dose-escalation study of intravenously (IV) administered TAK-676, a novel STING agonist, alone and in combination with pembrolizumab in patients (pts) with advanced or metastatic solid tumors.
First Author: Gerald Steven Falchook
Poster
2021 ASCO Annual Meeting
A phase 1b, open-label, dose-escalation study to evaluate camidanlumab tesirine (Cami) as monotherapy in patients (pts) with advanced solid tumors.
First Author: Igor Puzanov